{"disease":{"id":"leukemia-lymphocytic-chronic-b-cell","name":"leukemia lymphocytic chronic b cell"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00626496","title":"Family Study of Lymphoproliferative Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05947851","title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":735,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03289182","title":"An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)","phase":"","overall_status":"COMPLETED","enrollment_count":701,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03425591","title":"A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":508,"lead_sponsor_name":"Janssen-Cilag Ltd.","has_results":false},{"nct_id":"NCT03331198","title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":false},{"nct_id":"NCT05963074","title":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03720561","title":"A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting","phase":"","overall_status":"COMPLETED","enrollment_count":312,"lead_sponsor_name":"Janssen-Cilag S.p.A.","has_results":false},{"nct_id":"NCT03900598","title":"A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03462719","title":"A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":211,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT01865617","title":"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT06299540","title":"Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia","phase":"","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Janssen Cilag S.A.S.","has_results":false},{"nct_id":"NCT05424822","title":"A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":167,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02661035","title":"Allo HSCT Using RIC for Hematological Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03746392","title":"Project to Improve Communication About Serious Illness - Pilot Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT03246906","title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT04540796","title":"A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT00719888","title":"Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT06364423","title":"Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06788509","title":"A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":120,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02842229","title":"A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms","phase":"","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT02733042","title":"A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04849416","title":"A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT00545714","title":"A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04210219","title":"A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04271410","title":"CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT01251575","title":"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT03190330","title":"A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Johnson & Johnson Private Limited","has_results":true},{"nct_id":"NCT01822509","title":"Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04290923","title":"Determination of Blood Tumor Cells","phase":"","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT01760655","title":"Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT02454270","title":"A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":59,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05805605","title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT02213913","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT05418088","title":"Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Sumithira Vasu","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT01158118","title":"Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT02406742","title":"A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04876092","title":"A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03263637","title":"Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01129193","title":"AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Amir Mortazavi","has_results":false},{"nct_id":"NCT04271800","title":"Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT03476655","title":"Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Johnson & Johnson Private Limited","has_results":false},{"nct_id":"NCT03128359","title":"High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT06859008","title":"Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT01296932","title":"BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}